The Rise of Salivary Diagnostics

Life In Science

An interview with Dr. David Wong, Felix & Mildred Yip Professor and Director of the Center for Oral/Head & Neck Oncology Research at University of California Los Angeles.

Read more

Point of Care Diagnostics - A Cautious Revolution

Article

Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.

Read more

Lab-on-a-Chip to Help Detect Cancer

Podcast

In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.

Listen Now

Challenges of Developing Paper Based Diagnostic Devices

Video

John Brennan, Professor and Director, Biointerfaces Institute, McMaster University tells us about some of the challenges of developing paper based diagnostic devices.

Watch Now

What Tears Can Tell Us About Our Nutritional Health

Article

Adrienne R. Minerick, Associate Dean for Research & Innovation, College of Engineering, Michigan Technological University, tells us about the potential that tears can offer as an indicator of nutritional health.

Read more
Neurodegeneration Linked To Concussion

Neurodegeneration Linked To Concussion

Researchers provide evidence that mild traumatic brain injury is associated with greater neurodegeneration and reduced memory performance in people genetically at risk of Alzheimer's Disease.

Read more
 
Precision Medicine for Pediatric Brain Tumors a Reality

A clinical study has demonstrated the positive role that precision medicine can have on the care of pediatric brain cancer patients.

Read more

Disrupted GPS In Alzheimer's Linked To Tau Pathology In Entorhinal Cortex

Pathological Tau kills excitatory neurons on entorhinal cortex leading to misalignment of grid fields and deterioration of spatial cognition.

Read more

Immunoprofiler Iniative Launched By UCSF And Pharma

University of California San Francisco will partner with AbbVie, Amgen and Bristol Myers Squibb to analyse at least 500 tumour samples for immunologically relevant characteristics.

Read more